4-(2-Fluorophenyl)-2-oxobut-3-enoic acid | 1246278-36-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 4-(2-Fluorophenyl)-2-oxobut-3-enoic acid
• CAS: 1246278-36-3
• 化学式: C₁₀H₇FO₃
• 分子量: 194.162
• InChiKey: ILVHIFBHXAZUFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(2-Fluorophenyl)-2-oxobut-3-enoic acid 、 (R)-(+)-莰胺 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 4-(2-fluorophenyl)-2-oxo-N-[(1R,2S,4R)-1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl]but-3-enamide
  参考文献：
  名称：

  新型吡唑啉甲酰胺两类不同的有效大麻素CB 1受体激动剂

  摘要：

  的3-烷基-4-芳基-4,5-二氢吡唑-1-羧酰胺的合成和SAR 1 - 23和1-烷基-5-芳基-4,5-二氢吡唑-3-甲酰胺24 - 27作为两个新的大麻素描述了CB 1受体激动剂类别。目标化合物引起对CB 1和CB 2受体的高亲和力，并被发现可作为CB 1受体激动剂。关键化合物19在体外引起强效的CB 1激动剂和CB 2反向激动剂特性，并且在啮齿动物模型中口服给药后在多发性硬化中表现出体内活性。

  DOI：

  10.1016/j.bmcl.2010.07.056

文献信息

• 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS
  申请人：Lange Josephus H.M.

  公开号：US20090082396A1

  公开（公告）日：2009-03-26

  The invention is directed to 5-(hetero)aryl-4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives as cannabinoid CB 1 receptor agonists, to pharmaceutical compositions comprising these compounds, to methods for their syntheses, methods for preparing novel intermediates useful for their syntheses, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, administered to patients to achieve a therapeutic effect in disorders in which CB 1 receptors are involved, or that can be treated via manipulation of those receptors. Compounds of the present invention include compounds of formula (I): wherein the substituents have the definitions given in the specification.

  这项发明涉及作为大麻素CB1受体激动剂的5-(杂)芳基-4,5-二氢-吡唑啉（吡唑啉）衍生物，包括这些化合物的制药组合物，用于它们的合成方法，用于制备有用于它们的合成的新中间体的方法，以及用于制备组合物的方法。该发明还涉及这些化合物和组合物的用途，将其用于患者，以在涉及CB1受体的疾病中实现治疗效果，或者可以通过操纵这些受体来治疗的疾病。本发明的化合物包括式（I）的化合物，其中取代基具有规范中给定的定义。
• 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES AS CANNABINOID CB1 RECEPTOR AGONISTS
  申请人：Abbott Healthcare Products B.V.

  公开号：EP2203427A2

  公开（公告）日：2010-07-07
• US7928134B2
  申请人：——

  公开号：US7928134B2

  公开（公告）日：2011-04-19
• [EN] 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES AS CANNABINOID CB1 RECEPTOR AGONISTS<br/>[FR] 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES EN TANT QU'AGONISTES DES RÉCEPTEURS CANNABINOÏDES CB1
  申请人：SOLVAY PHARM BV

  公开号：WO2009037244A2

  公开（公告）日：2009-03-26

  This invention relates to 5-(hetero)aryl-4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives as cannabinoid CB1 receptor agonists, to pharmaceutical compositions containing these compounds, to methods for their syntheses, methods for preparing novel intermediates useful for their syntheses, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in disorders in which CB1 receptors are involved, or that can be treated via manipulation of those receptors. The compounds have the general Formula (I), wherein the symbols have the meanings given in the specification.
• Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists
  作者：Jos H.M. Lange、Amos Attali、Martina A.W. van der Neut、Henri C. Wals、Arie Mulder、Hicham Zilaout、Ate Duursma、Hans H.M. van Aken、Bernard J. van Vliet

  DOI：10.1016/j.bmcl.2010.07.056

  日期：2010.9

  The synthesis and SAR of 3-alkyl-4-aryl-4,5-dihydropyrazole-1-carboxamides 1–23 and 1-alkyl-5-aryl-4,5-dihydropyrazole-3-carboxamides 24–27 as two novel cannabinoid CB1 receptor agonist classes were described. The target compounds elicited high affinities to the CB1 as well as the CB2 receptor and were found to act as CB1 receptor agonists. The key compound 19 elicited potent CB1 agonistic and CB2 inverse

  的3-烷基-4-芳基-4,5-二氢吡唑-1-羧酰胺的合成和SAR 1 - 23和1-烷基-5-芳基-4,5-二氢吡唑-3-甲酰胺24 - 27作为两个新的大麻素描述了CB 1受体激动剂类别。目标化合物引起对CB 1和CB 2受体的高亲和力，并被发现可作为CB 1受体激动剂。关键化合物19在体外引起强效的CB 1激动剂和CB 2反向激动剂特性，并且在啮齿动物模型中口服给药后在多发性硬化中表现出体内活性。